J&J Pits Medivir's TMC435 Against Vertex's Incivek
By Cormac Sheridan
Wednesday, March 14, 2012
Johnson & Johnson, in a sense, is going head to head with itself by pitting its investigational protease inhibitor, TMC435, which it in-licensed from Medivir AB, against telaprevir, the hepatitis C virus (HCV) drug it markets as Incivo in Europe, Latin America, India and several other regions, in a Phase III trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.